Clinical trial NCT02879760 is a phase-I study focusing on understanding the efficacy of oncolytic MG1-MAGEA3 with Ad-MAGEA3 vaccine in combination with pembrolizumab in NSCLC. Here, MAGEA3 is linked to non-small cell lung carcinoma.